Clinical Trials Logo

Clinical Trial Summary

This phase II trial studies how well inotuzumab ozogamicin works in treating patients with CD22 positive acute lymphoblastic leukemia that has come back or does not respond to treatment. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a toxic agent called ozogamicin. Inotuzumab attaches to CD22 positive cancer cells in a targeted way and delivers ozogamicin to kill them.


Clinical Trial Description

PRIMARY OBJECTIVES: I. To evaluate the objective response rate of low dose of inotuzumab ozogamicin as measured by the hematologic remission rate (complete remission [CR] + CR with incomplete platelet recovery [CRp] + CR with incomplete bone marrow recovery [CRi]) in patients in first, second or later salvage setting. SECONDARY OBJECTIVES: I. To evaluate the overall safety profile and the efficacy; the efficacy is measured by the hematologic response rate (CR + CRi + PR), durations of response (DoR) and remission (DoR1), progression free survival (PFS), and overall survival (OS). OUTLINE: Patients receive inotuzumab ozogamicin intravenously (IV) over 1 hour on days 1, 8 and 15 of cycle 1 and on days 1 and 8 beginning cycle 2. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients whose disease gets worse after responding for 3 months, may be retreated for up to 6 additional cycles. Patients whose disease responds to treatment may receive up to 5 additional cycles. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03094611
Study type Interventional
Source M.D. Anderson Cancer Center
Contact
Status Terminated
Phase Phase 2
Start date November 30, 2017
Completion date March 11, 2020

See also
  Status Clinical Trial Phase
Active, not recruiting NCT03620058 - CART22 Alone or in Combination With huCART19 for ALL Phase 1
Completed NCT02551718 - High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia N/A
Recruiting NCT04888442 - Phase I Study of pCAR-19B in the Treatment of Adult CD19-positive Relapsed/Refractory B-ALL Phase 1
Suspended NCT03128034 - 211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia Phase 1/Phase 2
Withdrawn NCT03739606 - Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer Phase 2
Recruiting NCT03241940 - Phase I Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies Phase 1
Active, not recruiting NCT02146924 - Cellular Immunotherapy in Treating Patients With High-Risk Acute Lymphoblastic Leukemia Phase 1
Recruiting NCT04000698 - Personalized Targeted Preparative Regimen Before T-depleted Allogeneic HSCT in Children With Chemoresistent Acute Leukemias Phase 3
Completed NCT03096782 - Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma Phase 2
Completed NCT03575325 - Vyxeos(CPX-351) in Adults w R/R Acute Lymphoblastic Leukemia Phase 2
Completed NCT04888468 - Phase I Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents Phase 1
Recruiting NCT02392572 - ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome Phase 1/Phase 2
Recruiting NCT03263572 - Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia Phase 2
Terminated NCT03519984 - EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With Recurrent or Refractory Acute Leukemia Phase 1
Completed NCT04562792 - Low Dose Daunorubicin in Pediatric Relapsed/Refractory Acute Leukemia Phase 2
Active, not recruiting NCT01619761 - NK Cells in Cord Blood Transplantation Phase 1
Completed NCT01865617 - Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia Phase 1/Phase 2
Recruiting NCT02727803 - Personalized NK Cell Therapy in CBT Phase 2
Terminated NCT01620216 - Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia Phase 2
Recruiting NCT04340167 - Study of Anti-CD22 CAR-T Cells Treating Leukemia Children Phase 2